September 16th 2024
Your daily dose of the clinical news you may have missed.
September 11th 2024
EASD 2024: New data shows survodutide may be beneficial for persons with obesity and MASH.
September 10th 2024
September 9th 2024
Once-daily oral TERNS-601 was associated with a significant mean 5% weight reduction after 28 days and had a favorable tolerability profile.
Semaglutide Linked to Lower Risk of Suicidal Ideation in Patients with Obesity, Type 2 Diabetes
Semaglutide was associated with a lower risk of first-time and recurrent suicidal ideations in patients with obesity or overweight or T2D, according to new study.
Elinzanetant Meets Safety, Efficacy Endpoints in Phase 3 Studies Of Menopausal VMS
The novel nonhormonal compound significantly reduced vasomotor symptoms and sleep disturbance while improving quality of life, according to findings.
NAFLD Linked to Adverse Outcomes Regardless of BMI, New Research Suggests
Individuals with "lean NAFLD" may be at similar risk of NASH, cirrhosis, nonliver cancer, and death as as those with NAFLD and overweight or obesity, authors say.
Eli Lilly Open Letter Warns Against Use of Tirzepatide for "Cosmetic Weight Loss"
In an open letter to the public, Lilly decries use of tirzepatide products Mounjaro and Zepbound for nonmedical purposes and warns of counterfeit formulations.
Daily Dose: Tirzepatide Discontinuation Results in Weight Regain
Obesity Medicine Certificates Increase 40% from 2022 to 2023, says ABOM
The American Board of Obesity Medicine says annual first-time certificates now exceed those for cardiology, pulmonology, and medical oncology.
Tirzepatide Demonstrates Sustained Weight Loss but Discontinuation Results in Weight Regain: SURMOUNT-4 Trial
Study participants randomized to placebo for 1 year after 36 weeks on tirzepatide had mean weight regain of 14% vs augmented loss among those who continued on the medication.
Obesity: How Can America Afford to Treat the Disease?
While incretin-based antiobesity medications are the optimal treatment for some, there are other less costly approaches that can support weight loss success, this author says.
Tirzpatide for Chronic Weight Management Now Available in US Pharmacies, Lilly Announces
The dual GIP/GLP-1 mimetic is available by prescription for adults with obesity or overweight with comorbidities and Lilly is offering a savings card program.
FDA Grants Breakthrough Therapy Designation for Oral Congenital Adrenal Hyperplasia Medication
Crinecerfont was granted FDA breakthrough therapy designation for the treatment of congenital adrenal hyperplasia.
Daily Dose: Cardiovascular Risk Factors Rising Among Middle-Aged Americans
Obesity Advocacy Groups Say Exclusion of People with Obesity from Drug Research Must Stop
The 5 leading advocacy groups said the safety of people with obesity is at risk and called on the FDA to change clinical trial inclusion requirements and expedite labeling changes.
Daily Dose: COVID-19, Opioid Epidemic Primary Drivers of Widening Gender Gap in Life Expectancy
Primary Prevention of ASCVD: A Guideline Topline for Primary Care
Review the ACC/AHA guidelines on prevention of ASCVD through lifestyle and risk factor assessment and management in our at-a-glance slide show.
CV Risk Factors Increasing Among Middle-Aged US Adults, Socioeconomic Inequities Persist: New Findings
Cardiovascular mortality has been increasing among middle-aged US adult since 2011; a new study looked at changes in CV risk factors by income level over the past 20 years.
How to Build Assessment for Cardiovascular-Kidney-Metabolic Syndrome into Primary CVD Prevention
Chiadi Ndumele, MD, PhD, MHS, offers 3 thoughts for primary care on incorporating CKM syndrome screening into daily clinical practice.
Primary Care is the Quarterback in Effective Care for Cardiovascular-Kidney-Metabolic Syndrome
"Primary care physicians... really are like the quarterbacks" for initiating multidisciplinary care for CKM syndrome, says Dr Chiadi Ndumele.
New CVD Risk Equations are Sex-Specific, Exclude Race, Include eGFR, and Predict Heart Failure
Absolute risk assessment for CVD remains the corner-stone of clinical primary prevention efforts. The new AHA prediction models expand that foundation.
Daily Dose: Semaglutide Cuts CV Risk by 20% in Adults with Obesity, CVD and Without DM
We Need to Shift Social Determinants of Health into Our Clinical Workflow, says Chiadi Ndumele, MD, PhD, MHS
Managing cardiovascular-kidney-metabolic syndrome on a population-wide basis requires that social determinants of health be treated like any other risk factor, according to Ndumele.
AHA Proposes Redefined CVD Risk Calculation in Cardiovascular Kidney Metabolic Syndrome
Dr Chiadi Ndumele explains the need for the more comprehensive and also nuanced qualitative approach to estimating long-term CVD risk.
The 4 Stages of CKM Syndrome Offer Opportunities to Stop Progression, Promote Regression
Chiadi Ndumele, MD, PhD, MHS, of Johns Hopkins University, details features of the new 4-stage construct that guides CKM diagnosis and promotes early disease intervention.
Tirzepatide Approved by FDA for Chronic Weight Management in Adults
The second GLP-1 mimetic-based drug approved for chronic weight management, tirzepatide may outperform semaglutide, the first.
It's High Time to Retire NAFLD: Multinational Liver Societies Explain
NAFLD, a term coined in the mid-nineteenth century but never an accurate name for the diseases it now stands for, was ready to go, agreed international experts.
Daily Dose: Tirzepatide Preferred GLP-1 Agonist for Inducing Weight Loss
Tirzepatide Ups Mean Weight Loss by 21% Following Intensive Lifestyle Intervention: SURMOUNT-3
Tirzepatide could help individuals who lose weight with lifestyle change to maintain and augment that loss, a well known challenge among persons with obesity.
Tirzepatide Ranked Most Effective GLP-1 Mimetic for Obesity Management in New Meta-Analysis
The 2 highest doses of tirzepatide were ranked most likely to be effective for weight management in persons without diabetes, followed by semaglutide 2.4 mg.
AHA Defines Cardiovascular-Kidney-Metabolic Syndrome, Redefines CVD Risk, Prevention, Management
A new paradigm for reducing CV morbidity and mortality provides a comprehensive approach to comorbid metabolic disease including early detection and treatment.
Novo Stops Semaglutide Kidney Outcomes Trial Early for Efficacy
The phase 3 semaglutide kidney outcomes trial will be stopped immediately with FLOW read out expected in early 2024, the company said.
Daily Dose: Biosimilar Liraglutide Found Safe, Effective for Use in Patients with T2D